Suppr超能文献

超高 D-二聚体水平的临床意义。

The clinical significance of ultra-high D-dimer levels.

机构信息

University of Toledo College of Medicine, Toledo, Ohio.

Jobst Vascular Institute, Toledo, Ohio.

出版信息

J Vasc Surg Venous Lymphat Disord. 2022 Jan;10(1):8-13. doi: 10.1016/j.jvsv.2021.06.011. Epub 2021 Jun 23.

Abstract

OBJECTIVE

Plasma D-dimer levels >5000 ng/mL are encountered in a number of conditions other than venous thromboembolism (VTE). Recent studies have used plasma D-dimer levels as a prognostic indicator for coronavirus disease 2019 (COVID-19) infection. The implications of abnormal levels are less clear for patients diagnosed with COVID-19 with a baseline elevation in plasma D-dimer levels. In the present study, we reviewed the occurrence of plasma D-dimer levels >5000 ng/mL and investigated the clinical significance of this finding before the onset of the COVID-19 pandemic.

METHODS

Inpatient records for a 4-year period were screened for laboratory results of plasma D-dimer levels >5000 ng/mL. The patient data were reviewed for the clinical identifiers commonly associated with elevated plasma D-dimer levels, including VTE, cancer, sepsis, pneumonia, other infection, bleeding, and trauma. The patients were then categorized into groups stratified by the plasma D-dimer level to allow for comparisons between the various clinical diagnoses.

RESULTS

A total of 671 patients were included in the present study. VTE was the most common diagnosis for patients with a plasma D-dimer level >5000 ng/mL, followed by cancer and pneumonia. Multiple clinical diagnoses were present in 61% of the patients. No clear cause for the ultra-high plasma D-dimer level could be identified in 11.3% of the patients. Among the patients lacking a clinical diagnosis at discharge, mortality was 24% in the 5000- to 10,000-ng/mL group, 28.6% in the 10,000- to 15,000-ng/mL group, and 75% in the >15,000-ng/mL group.

CONCLUSIONS

VTE, cancer, and pneumonia were frequently present when ultra-high plasma D-dimer levels were encountered, and mortality was high when the levels were >15,000 ng/mL. The results from our study from a pre-COVID-19 patient population suggest that ultra-high plasma D-dimer levels indicate the presence of severe underlying disease. This should be considered when using the plasma D-dimer level as a screening tool or prognostic indicator for COVID-19 infection.

摘要

目的

除静脉血栓栓塞症(VTE)外,许多情况下也会出现血浆 D-二聚体水平>5000ng/ml。最近的研究已将血浆 D-二聚体水平用作 2019 年冠状病毒病(COVID-19)感染的预后指标。对于基线血浆 D-二聚体水平升高的 COVID-19 患者,异常水平的影响尚不明确。在本研究中,我们回顾了 COVID-19 大流行前出现血浆 D-二聚体水平>5000ng/ml 的情况,并研究了这一发现的临床意义。

方法

对 4 年期间的住院患者记录进行筛查,以获取血浆 D-二聚体水平>5000ng/ml 的实验室结果。为与升高的血浆 D-二聚体水平相关的常见临床指标回顾患者数据,包括 VTE、癌症、脓毒症、肺炎、其他感染、出血和创伤。然后,根据血浆 D-二聚体水平将患者分为不同的组,以便对各种临床诊断进行比较。

结果

本研究共纳入 671 例患者。血浆 D-二聚体水平>5000ng/ml 的患者最常见的诊断为 VTE,其次为癌症和肺炎。61%的患者存在多种临床诊断。在 11.3%的患者中,无法明确超高血浆 D-二聚体水平的原因。在出院时无临床诊断的患者中,5000-10000ng/ml 组的死亡率为 24%,10000-15000ng/ml 组为 28.6%,>15000ng/ml 组为 75%。

结论

当出现超高血浆 D-二聚体水平时,常伴有 VTE、癌症和肺炎,当水平>15000ng/ml 时死亡率较高。本研究来自 COVID-19 前的患者人群,结果表明超高血浆 D-二聚体水平表明存在严重的潜在疾病。在将血浆 D-二聚体水平用作 COVID-19 感染的筛查工具或预后指标时,应考虑到这一点。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/29e4/8220196/03409841cdd2/fx1_lrg.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验